ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last3,481 to 3,500 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Human Rotavirus (HRV) Group vs HRV Porcine Circovirus (PCV)-Free Group: serious adverse events251 of 998

262 of 1,002

-1.0 points

-4.8 to 2.8

2,000NCT06025695

Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix Porcine Circovirus (PCV)-Free Liquid Compared to Rotarix Liquid Given in 2-doses in Healthy Chinese Infants Starting at Age 6-16 Weeks

Liberal (10 g/dL) Transfusion Strategy vs Restrictive Strategy: Inability to Walk 10 Feet or Across a Room Without Human Assistance or Death351 of 998

347 of 1,001

0.5 points

-3.7 to 4.7

1,999NCT00071032

Safety and Effectiveness of Two Blood Transfusion Strategies in Surgical Patients With Cardiovascular Disease

Liberal (10 g/dL) Transfusion Strategy vs Restrictive Strategy: Mortality at 60 Days76 of 998

66 of 1,001

1.0 points

-1.2 to 3.3

1,999NCT00071032

Safety and Effectiveness of Two Blood Transfusion Strategies in Surgical Patients With Cardiovascular Disease

Male Group vs Female Group: Number of Subjects With Anti-PT IgG Levels Not Indicative of Current/Recent Infection (by Gender)775 of 787

1,202 of 1,212

-0.7 points

-1.9 to 0.2

1,999NCT02014519

A Study to Determine the Seroprevalence of Bordetella Pertussis in Adults in Hungary

Female Group vs Male Group: Number of Seropositive Subjects in Terms of Anti-PT Concentrations (by Gender)160 of 1,212

135 of 787

-4.0 points

-7.3 to -0.8

1,999NCT02014519

A Study to Determine the Seroprevalence of Bordetella Pertussis in Adults in Hungary

Female Group vs Male Group: Number of Subjects With Anti-PT IgG Levels Indicative of Current/Recent Infection (by Gender)10 of 1,212

12 of 787

-0.7 points

-1.9 to 0.2

1,999NCT02014519

A Study to Determine the Seroprevalence of Bordetella Pertussis in Adults in Hungary

Female Group vs Male Group: Number of Seronegative Subjects in Terms of Anti-PT Concentrations (by Gender)1,052 of 1,212

652 of 787

4.0 points

0.8 to 7.3

1,999NCT02014519

A Study to Determine the Seroprevalence of Bordetella Pertussis in Adults in Hungary

Female Group vs Male Group: Number of Subjects With Anti-PT IgG Levels Strongly Indicative of Current/Recent Infection (by Gender)0 of 1,212

2 of 787

-0.3 points

-0.9 to 0.1

1,999NCT02014519

A Study to Determine the Seroprevalence of Bordetella Pertussis in Adults in Hungary

Standard WBI vs WBI, Trastuzumab: deaths from any cause11 of 1,005

10 of 993

0.1 points

-0.9 to 1.1

1,998NCT00769379

Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

Liberal (10 g/dL) Transfusion Strategy vs Restrictive Strategy: Disposition Status (i.e., Nursing Home Placement)137 of 996

161 of 1,001

-2.3 points

-5.5 to 0.8

1,997NCT00071032

Safety and Effectiveness of Two Blood Transfusion Strategies in Surgical Patients With Cardiovascular Disease

Ferumoxytol vs Ferric Carboxymaltose (FCM): serious adverse events36 of 997

35 of 1,000

0.1 points

-1.5 to 1.8

1,997NCT02694978

A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)

Direct Admission vs ED Admission: Number of Participants With Clinical Deterioration1 of 145

15 of 1,852

-0.1 points

-0.9 to 3.0

1,997NCT04192799

Comparative Effectiveness of Direct Admission & Admission Through Emergency Departments for Children

ENG-E2 125 μg/300 μg vs LNG-EE 150 μg/30 μg: Number of Participants Who Experienced an Adverse Event (AE)530 of 1,504

140 of 492

6.8 points

2.0 to 11.3

1,996NCT02616146

Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring and Levonorgestrel-Ethinyl Estradiol Combined Oral Contraceptive in Adult Women at Risk for Pregnancy (MK-8342B-062)

ENG-E2 125 μg/300 μg vs LNG-EE 150 μg/30 μg: Number of Participants Who Discontinued Treatment Due to an AE61 of 1,504

23 of 492

-0.6 points

-3.0 to 1.3

1,996NCT02616146

Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring and Levonorgestrel-Ethinyl Estradiol Combined Oral Contraceptive in Adult Women at Risk for Pregnancy (MK-8342B-062)

ENG-E2 125 μg/300 μg vs LNG-EE 150 μg/30 μg: serious adverse events8 of 1,504

3 of 492

-0.1 points

-1.3 to 0.6

1,996NCT02616146

Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring and Levonorgestrel-Ethinyl Estradiol Combined Oral Contraceptive in Adult Women at Risk for Pregnancy (MK-8342B-062)

Liberal (10 g/dL) Transfusion Strategy vs Restrictive Strategy: Mortality at 30 Days52 of 995

43 of 1,000

0.9 points

-1.0 to 2.8

1,995NCT00071032

Safety and Effectiveness of Two Blood Transfusion Strategies in Surgical Patients With Cardiovascular Disease

Dabigatran 220mg vs Enoxaparin: Number of Participants Who Died During Treatment Period0 of 1,001

1 of 992

-0.1 points

-0.6 to 0.3

1,993NCT00657150

Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty

Dabigatran 220mg vs Enoxaparin: Number of Participants With Symptomatic Deep Vein Thrombosis During Treatment Period0 of 1,001

4 of 992

-0.4 points

-1.0 to 0.1

1,993NCT00657150

Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty

Dabigatran 220mg vs Enoxaparin: Number of Participants With Pulmonary Embolism During Treatment Period1 of 1,001

2 of 992

-0.1 points

-0.6 to 0.4

1,993NCT00657150

Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty

Montelukast 10 mg vs Placebo: serious adverse events4 of 1,002

1 of 990

0.3 points

-0.2 to 0.9

1,992NCT00092118

The Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis (0476-265)

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=175"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=175

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT06025695-sae",
        "title": "Human Rotavirus (HRV) Group vs HRV Porcine Circovirus (PCV)-Free Group: serious adverse events",
        "summary": "251 of 998 against 262 of 1002; risk difference -1.0 points, 95% interval -4.8 to 2.8; NCT06025695, Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix Porcine Circovirus (PCV)-Free Liquid Compared to Rotarix Liquid Given in 2-doses in Healthy Chinese Infants Starting at Age 6-16 Weeks",
        "record": "/library/comparisons/NCT06025695-sae",
        "nct_id": "NCT06025695",
        "kind": "serious-adverse-events",
        "participants": 2000,
        "risk_difference": {
          "value": -0.009974039896159637,
          "lower": -0.0481980603663736,
          "upper": 0.028295107923809897
        },
        "group_1": "251 of 998",
        "group_2": "262 of 1,002",
        "difference": "-1.0 points",
        "interval": "-4.8 to 2.8",
        "trial_title": "Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix Porcine Circovirus (PCV)-Free Liquid Compared to Rotarix Liquid Given in 2-doses in Healthy Chinese Infants Starting at Age 6-16 Weeks"
      },
      {
        "id": "NCT00071032-c7b04be3",
        "title": "Liberal (10 g/dL) Transfusion Strategy vs Restrictive Strategy: Inability to Walk 10 Feet or Across a Room Without Human Assistance or Death",
        "summary": "351 of 998 against 347 of 1001; risk difference 0.5 points, 95% interval -3.7 to 4.7; NCT00071032, Safety and Effectiveness of Two Blood Transfusion Strategies in Surgical Patients With Cardiovascular Disease",
        "record": "/library/comparisons/NCT00071032-c7b04be3",
        "nct_id": "NCT00071032",
        "kind": "outcome",
        "participants": 1999,
        "risk_difference": {
          "value": 0.005050060160280645,
          "lower": -0.03669107442293068,
          "upper": 0.046770243504720005
        },
        "group_1": "351 of 998",
        "group_2": "347 of 1,001",
        "difference": "0.5 points",
        "interval": "-3.7 to 4.7",
        "trial_title": "Safety and Effectiveness of Two Blood Transfusion Strategies in Surgical Patients With Cardiovascular Disease"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=176",
  "request_id": "W9bkI8mFFnv8dLfY"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?